Natick’s Boston Scientific Corp. announced that the U.S. Food and Drug Administration has approved a new device for the minimally invasive treatment of uterine fibroids, liver cancer and other conditions.
BSX said it will begin a U.S. launch right away for the product, called the Renegade Hi-Flo Fathom Pre-Loaded System.
The company said the device will reduce prep time for procedures and allow medical staff to use fewer devices.
